Development of individualized mRNA neoantigen vaccines for pancreatic cancer

Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the challenges of using immunotherapy for pancreatic cancer and explains how investigation of a rare subset of patients who have spontaneous immune activation in primary tumors has led to the development of mRNA neoantigen vaccines for patients who do not undergo spontaneous immune activation. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

• categorie